About

The Albumin-to-Creatinine Ratio (ACR) quantifies urinary albumin excretion normalized to creatinine concentration, eliminating the need for timed urine collections. A spot urine ACR ≥ 30 mg/g sustained over three months satisfies the KDIGO criterion for chronic kidney disease category A2 or higher, independent of glomerular filtration rate. Failing to detect persistent albuminuria delays intervention in diabetic nephropathy, hypertensive nephrosclerosis, and IgA nephropathy, accelerating progression to end-stage renal disease. This calculator converts albumin and creatinine inputs across common laboratory units and classifies the result against the KDIGO 2012 albuminuria staging system.

Limitations: a single spot sample carries biological variability of ±40% due to hydration status, exercise, fever, and diurnal rhythm. Confirmation requires two additional positive samples within 3-6 months. Creatinine excretion differs by muscle mass, so very muscular or cachectic patients may be misclassified. Pro tip: first-void morning specimens reduce orthostatic and activity-related false positives.

Formulas

The Albumin-to-Creatinine Ratio is computed by dividing the urine albumin concentration by the urine creatinine concentration, with appropriate unit normalization:

ACR = AlbuminCreatinine

When albumin is measured in mg/L and creatinine in mg/dL, the result is first obtained in mg/L per mg/dL. To express ACR in the standard mg/g:

ACR (mg/g) = Albumin (mg/L)Creatinine (mg/dL) × 0.01 (g/L per mg/dL)

This simplifies to multiplying the raw ratio by 100. To convert to SI units:

ACR (mg/mmol) = ACR (mg/g)8.84

Where Albumin = urine albumin concentration from a spot sample. Creatinine = urine creatinine concentration from the same specimen. The factor 8.84 derives from the molar mass of creatinine (113.12 g/mol) converting g to mmol: 1000 ÷ 113.12 ≈ 8.84. The constant 0.01 converts mg/dL to g/L for creatinine.

Reference Data

KDIGO Category	ACR Range (mg/g)	ACR Range (mg/mmol)	Clinical Term	Daily Albumin Excretion (mg/day)	Risk Implication
A1	< 30	< 3	Normal to mildly increased	< 30	Low risk (reference)
A2	30 - 300	3 - 30	Moderately increased (Microalbuminuria)	30 - 300	Moderate risk; initiate ACEI/ARB
A3	> 300	> 30	Severely increased (Macroalbuminuria)	> 300	High risk; nephrology referral
Common Reference Values by Population
Healthy adult	< 10	< 1.1	Normal	< 10	Baseline
Diabetes (Type 1 & 2)	30 - 300	3 - 30	Early nephropathy screening threshold	30 - 300	Annual screening recommended
Hypertension	≥ 30	≥ 3	Target organ damage marker	≥ 30	Blood pressure target adjustment
Cardiovascular risk	≥ 10	≥ 1.1	Independent CV risk factor	-	Continuous risk relationship
Pregnancy (preeclampsia screen)	≥ 30	≥ 3	Abnormal	≥ 30	Obstetric monitoring required
Sex-Specific Cutoffs (ADA Recommended)
Male	≥ 17	≥ 2.5	Abnormal threshold (some guidelines)	-	Higher creatinine excretion baseline
Female	≥ 25	≥ 3.5	Abnormal threshold (some guidelines)	-	Lower muscle mass = lower creatinine
Unit Conversion Factors
Creatinine	1 mg/dL = 88.4 μmol/L		Jaffé or enzymatic assay
Albumin	1 mg/dL = 10 mg/L		Immunoturbidimetry
ACR	1 mg/mmol ≈ 8.84 mg/g		SI ↔ conventional conversion

Frequently Asked Questions

A 24-hour collection is the gold standard for total albumin excretion but suffers from poor patient compliance and collection errors averaging 20-30% volume inaccuracy. The spot ACR normalizes albumin to creatinine, compensating for urine dilution. Multiple studies (NHANES, PREVEND) demonstrate a correlation coefficient of r ≈ 0.93 between spot ACR and 24-hour albumin excretion. KDIGO 2012 guidelines accept spot ACR as the primary screening method, preferably from a first-morning void.

Creatinine is a byproduct of skeletal muscle metabolism. A highly muscular patient excretes more creatinine, diluting the ratio and potentially masking true albuminuria (false-negative ACR). Conversely, a cachectic or elderly sarcopenic patient produces less creatinine, inflating the ACR (false-positive). Some guidelines (ADA) recommend sex-specific cutoffs: ≥ 17 mg/g for males and ≥ 25 mg/g for females to partially compensate for average differences in lean body mass.

Transient albuminuria not reflecting glomerular damage occurs with vigorous exercise within 24 hours, urinary tract infection, fever, congestive heart failure decompensation, menstrual contamination, and orthostatic proteinuria in young adults. Hematuria (dipstick-positive blood) also falsely elevates immunoassay-measured albumin. KDIGO requires at least 2 out of 3 positive samples over 3-6 months before confirming persistent albuminuria category A2 or A3.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduce intraglomerular pressure by dilating the efferent arteriole, lowering albumin filtration by 20-50% within weeks. A target ACR reduction of > 30% from baseline or achieving < 30 mg/g is considered a therapeutic success per KDIGO. Monitoring ACR 2-3 months after initiation or dose change is standard. If ACR does not decrease, non-adherence, progressive disease, or a non-albuminuric CKD phenotype should be considered.

Albuminuria is an independent risk factor for cardiovascular events. The CKD Prognosis Consortium meta-analysis of over 1 million participants showed that an ACR of 30 mg/g doubles the adjusted hazard ratio for cardiovascular mortality compared to ACR of 5 mg/g, and ACR of 300 mg/g increases it approximately 4-fold. This risk is continuous with no safe threshold - even ACR values of 10-29 mg/g (high-normal range) carry measurable excess risk.

Yes. In diabetic kidney disease, ACR typically progresses from A1 → A2 → A3 over years if glycemic and blood pressure control are inadequate. However, approximately 30% of type 2 diabetes patients develop GFR decline without preceding albuminuria (non-albuminuric diabetic kidney disease). KDIGO recommends monitoring both ACR and eGFR simultaneously at least annually in all diabetic patients and quarterly in those with ACR ≥ 300 mg/g or eGFR < 30 mL/min/1.73 m².